Fractyl rises after obesity gene therapy shows promise in preclinical trial

Fractyl Health

07/10/2025 12:54

** Shares of drug developer Fractyl Health GUTS.O rise 1.4% to $1.49 premarket

  ** Co says obesity gene therapy RJVA-002 showed ~30% weight loss in mice, in a preclinical trial

  ** The therapy is designed to trigger the production of appetite-suppressing hormones, GLP-1 and GIP

 ** Treatment with RJVA-002 resulted in a dose-dependent reduction in body weight - Fracty

      ** Up to last close, stock down ~28% YTD

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com;))